| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 35.89 mm | 35.89 mm | 35.89 mm | 35.89 mm | 35.89 mm | 35.89 mm |
| Cash burn (monthly) | (no burn) | 6.79 mm | 12.54 mm | 11.33 mm | 9.01 mm | 8.05 mm |
| Cash used (since last report) | n/a | 36.19 mm | 66.81 mm | 60.33 mm | 47.97 mm | 42.86 mm |
| Cash remaining | n/a | -301.72 k | -30.92 mm | -24.45 mm | -12.09 mm | -6.97 mm |
| Runway (months of cash) | n/a | -0.0 | -2.5 | -2.2 | -1.3 | -0.9 |
| 13F holders | Current |
|---|---|
| Total holders | 159 |
| Opened positions | 39 |
| Closed positions | 11 |
| Increased positions | 53 |
| Reduced positions | 41 |
| 13F shares | Current |
|---|---|
| Total value | 413.48 bn |
| Total shares | 86.31 mm |
| Total puts | 1.30 k |
| Total calls | 235.00 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 7.56 mm | $76.25 mm |
| Bain Capital Life Sciences Investors | 7.47 mm | $43.55 bn |
| Bain Capital Life Sciences Opportunities IV | 7.47 mm | $62.82 mm |
| Paradigm Biocapital Advisors | 7.30 mm | $42.59 bn |
| BVF | 5.72 mm | $33.32 bn |
| BlackRock | 3.79 mm | $22.09 bn |
| Point72 Asset Management | 3.67 mm | $21.40 bn |
| Deep Track Capital | 3.44 mm | $20.07 bn |
| Logos Global Management | 3.21 mm | $18.71 bn |
| MPM Oncology Impact Management | 2.91 mm | $16.98 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Feb 25 | Sean Bohen | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 650,000 | 2.84 mm | 650,000 |
| 28 Feb 25 | Shane William Charles Kovacs | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 320,000 | 1.40 mm | 320,000 |
| 28 Feb 25 | Mitchell Shawnte | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 450,000 | 1.97 mm | 450,000 |
| 28 Feb 25 | Naseem Zojwalla | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 205,000 | 895.85 k | 205,000 |
| 28 Feb 25 | David C. Myles | Stock Option Common Stock | Grant | Acquire A | No | No | 4.37 | 205,000 | 895.85 k | 205,000 |
